Literature DB >> 2200826

Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study.

C L Leen1, E M Dunbar, M E Ellis, B K Mandal.   

Abstract

Fluconazole 50 mg daily for 14-28 days was effective in the treatment of patients with AIDS and AIDS-related complex with severe oropharyngeal and oesophageal candidiasis. Of 24 patients entered, 17 (81%), including seven with oesophageal candidiasis, were clinically cured and two (9.5%) improved at the end of treatment. Following clinical cure, 14 patients were entered into the double-blind phase of the study, where fluconazole (150 mg) or placebo capsules were given once weekly. Treatment was double blind. Fluconazole 150 mg once weekly was found to be effective in maintaining patients both clinically and mycologically free of oropharyngeal candidiasis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200826     DOI: 10.1016/0163-4453(90)90646-p

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  15 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 3.  [Preventive antimycotic therapy of neutropenic and immunosuppressed patients].

Authors:  M Ruhnke; J Beyer
Journal:  Med Klin (Munich)       Date:  1997-01-15

Review 4.  Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.

Authors:  Elizabeth D Pienaar; Taryn Young; Haly Holmes
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 5.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 6.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26

7.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre Study Group [corrected].

Authors:  P Marchisio; N Principi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-04       Impact factor: 3.267

9.  Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole.

Authors:  M Ruhnke; A Eigler; E Engelmann; B Geiseler; M Trautmann
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

10.  Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.

Authors:  Frank-Michael C Müller; Andrea Staudigel; Stefanie Salvenmoser; Antje Tredup; Rudolf Miltenberger; Josef V Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.